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We conducted a non-randomised controlled phase II trial to investigate the role of preoperative administration of interleukin-2 (IL-2)
in patients with renal cell carcinoma undergoing tumour nephrectomy. A total of 120 consecutive patients were allocated alternately
to the two study groups: perioperative immunomodulation with IL-2 (IL-2 group; n¼60) and perioperative immunomonitoring
without immunomodulation (control group; n¼60). Patients from the IL-2 group received four doses of 10 10
6IUm
 2 twice daily
subcutaneously a week before operation followed by a daily maintenance dose of 3 10
6IUm
 2 subcutaneously until a day before
the operation. Parameters of cellular and humoral immunity (leucocytes, T-cell markers CD3, CD4, and CD8, B-cell marker CD19,
monocyte marker CD14, natural killer (NK) cell markers CD16, CD56, and CD57, activation markers CD6, CD25, CD28, and CD69,
progenitor cell marker CD34, as well as IL-2, IL-6, IL-10, soluble IL-2 receptor, IL-1 receptor antagonist, transforming growth factor-
b1, and vascular endothelial growth factor) were measured in peripheral venous blood at various intervals. Interleukin-2-related
toxicity was WHO grade 1 (24%), 2 (67%), and 3 (9%). In the postoperative period, T-cell markers, activation markers, and NK cell
markers decreased, and IL-6 and IL-10 increased. However, all these alterations were significantly less accentuated in patients who
had been pretreated with IL-2. Median follow-up was 40 months. Tumour-specific survival in the IL-2 group and the control group
was 98 vs 81% after 1 year and 86 vs 73% after 5 years (P¼0.04). A similar effect was found for progression-free survival. We
conclude that IL-2 can be safely administered in the perioperative period and modulates immunological parameters. However, to
validate the survival data, a larger randomised phase III trial is needed.
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Renal cell carcinoma (RCC) accounts for 3% of all adult
malignancies. Over 38000 new cases and 12000 deaths were
estimated for 2006 in the United States (Jemal et al, 2006). Surgery
is a mainstay of therapy for both localised and metastasised RCC.
However, surgery is associated with considerable perioperative
dysfunction of the immune system (Bo ¨hm et al, 2001). Also,
circulating tumour cells are frequently found in patients with RCC
(McKiernan et al, 1999; Ashida et al, 2000; Bilkenroth et al, 2001;
Shimazui et al, 2004) and are more prevalent in the renal vein and
after surgery (Ashida et al, 2000), possibly owing to surgery-
associated dissemination of tumour cells into the blood circula-
tion, and the presence of circulating tumour cells appears to be
associated with a poor prognosis (Shimazui et al, 2004).
Considered an immunosensitive disease, RCC is being treated
with various immunotherapeutic regimens both before and after
surgery. So far, no survival benefit has been demonstrated
(Pizzocaro et al, 2001; Clark et al, 2003; Messing et al, 2003;
Atzpodien et al, 2005; Bex et al, 2006). In these studies, no
immunotherapy was administered during the perioperative period
when immunodysfunction is most pronounced and circulating
tumour cells are most frequently detected.
On this background, we conducted a prospective controlled
phase II trial to assess the effect of immunomodulation with
interleukin-2 (IL-2) in the potentially critical perioperative period
in patients with RCC undergoing tumour nephrectomy.
PATIENTS AND METHODS
Study objectives and patient eligibility
Patients with a renal tumour who were scheduled for radical
nephrectomy at our institution were eligible for entry into this
phase II trial. Each patient met the following eligibility criteria: (a)
Eastern Cooperative Oncology Group performance status (ECOG
PS) of p2; (b) life expectancy 43 months; (c) age at least 18 years;
(d) adequate bone marrow, hepatic, and renal function; and (e)
negative pregnancy test for women of childbearing potential.
Exclusion criteria were as follows: no histologically proven RCC;
prior or synchronous malignancies; autoimmune diseases; preg-
nancy or lactation; uncontrolled infections; chronic debilitating
diseases; positive HIV status; and the presence of contraindica-
tions to IL-2.
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They were allocated alternately to the two study groups:
perioperative immunomodulation with IL-2 (IL-2 group; n¼60)
and perioperative immunomonitoring without immunomodula-
tion as a control group (control group; n¼60). The study was
approved by the local ethics committee.
Treatment and toxicity assessment
Recombinant human IL-2 (Aldesleukin, Chiron, Ratingen,
Germany) was administered subcutaneously for 6 days 1 week
before the operation starting with four initial high-dose injections
of 10 10
6 international units (IU)m
 2 twice daily followed by a
daily maintenance dose of 3 10
6IUm
 2 until 1 day before the
operation. The maintenance but not the initial dose was reduced if
toxicity was encountered. Co-medication during the initial high
IL-2 dose phase included the antipyretic metamizole (1g every 4h)
and the antimemetic metoclopramide on demand. Interleukin-2-
related toxicity was determined in a standardised way according to
the WHO classification: mild (grade 1), moderate (grade 2), and
severe (grade 3). Toxicity was monitored until 10 days after the
operation.
Immunological analyses
Peripheral venous blood was collected before and during the
administration of IL-2, in both study groups 1 day before and
immediately after the operation and on the first, third, fifth, and
tenth postoperative day. The blood sample was drawn early in the
morning after overnight fasting by puncture of an antecubital vein
of the arm.
Parameters in cellular and humoral immunity, including
differential blood count, T-cell markers CD3, CD4, and CD8, B-
cell marker CD19, monocyte marker CD14, natural killer (NK) cell
markers CD16, CD56, and CD57, activation markers CD6, CD25,
CD28, CD69, and HLA-DR, progenitor cell marker CD34, and
cytokine IL-1 receptor antagonist (IL-1-RA), IL-2, soluble IL-2
receptor (sIL2-R), IL-6, IL-10, transforming growth factor (TGF)-
b1, and vascular endothelial growth factor (VEGF), were measured
using standard technique and commercially available kits. Cellular
parameters: Whole blood (100ml, EDTA) was stained with
monoclonal antibodies conjugated with fluorescein isothiocyanate
(Becton Dickinson, Heidelberg, Germany), phycoerythrin (Becton
Dickinson), or PC5 (R-phycoerythrincyanin 5.1, Immunotech,
Marseille, France). Erythrocytes were lysed by incubation with
FACS lysing solution (Becton Dickinson, Heidelberg, Germany) for
15min, and leucocyte subsets were determined by flow cytometry
using a FACS Calibur (Becton Dickinson) with CellQuest Pro
software (Becton Dickinson). Cytokines: Citrate-supplemented
tubes were used and processed for plasma within 1h. After
centrifugation (3000r.p.m., 10min) and removal of the plasma, the
samples were stored at  801C until analysis. Cytokines were
analysed using commercial quantitative enzyme-linked immuno-
assays (Quantikine Human Immunoassays, R&D Systems GmbH,
Wiesbaden, Germany).
Follow-up and statistical analyses
Follow-up was surveyed according to the guidelines of the
European Association of Urology beginning 4–6 weeks after
surgery. Data are presented as the mean7standard error of the
mean (s.e.m.). Both univariate and multivariate analyses were
performed depending on the data subset and question to be
answered. Whenever possible, multivariate analyses were per-
formed in order to validate univariate statistics. Characteristics of
the two treatment groups were compared using the w
2-test and the
Student’s t-test for categorical and continuous variables, respec-
tively. The primary end points were the alterations in parameters
of cellular and humoral immunity. Secondary end points included
toxicity, tumour-specific survival, and time to progression.
Survival curves were determined using the Kaplan–Meier method
and calculated from the date of nephrectomy. For univariate
survival analysis, survival curves were compared using the log-
rank test. It should, however, be emphasised that extensive
subanalyses were limited because of the size of the patient
population. Nonetheless, we address survival analysis in patients
with stage IV RCC separately because of the different treatment
modalities these patients received. For multivariate survival
analysis, a Cox regression analysis was performed. Statistical
analysis was carried out using the SPSS (version 11.5) program. In
all analyses, the significance level was specified as Pp0.05.
RESULTS
Between May 1999 and September 2004, 120 consecutive patients
were enrolled. Four patients were withdrawn because histology
showed that they had no RCC. Therefore, the intention-to-treat
population consisted of 116 patients, with 58 in each study group.
The two study groups did not differ with respect to age, sex, ECOG
PS, tumour stage, tumour diameter, Thoenes grade, histological
subtype, location, operation time, operative technique, or peri-
operative blood transfusions. Table 1 summarises the patient and
tumour characteristics.
Toxicity
All patients who received IL-2 suffered from IL-2-related toxicity
grade 1 (24%), 2 (67%), or 3 (9%). Toxicity subsided usually the
day after the last high-dose IL-2 injection. Relevant toxicity criteria
are shown in Table 2.
Immunological analyses
For reasons of clarity and brevity, data are presented as plots.
Cellular markers and cytokines are shown in Figures 1 and 2,
respectively. Mean7s.e.m. are indicated.
During IL-2 treatment, T-cell markers (CD3, CD4, CD8),
activation markers (CD6, CD25, CD28, HLA-DR), B-cell marker
(CD19), and NK cell markers (CD16, CD56, CD57) decreased
significantly (day  7 vs  6), followed by an increase at the day of
operation. Progenitor cell marker CD34 did not change from day
 7 to day  6, but was significantly lower in the IL-2 group on day
 1. In the postoperative period, all patients showed elevated
leucocyte and granulocyte but decreased lymphocyte counts, T-cell
markers, activation markers, and NK cell markers. However, all
these alterations were significantly less pronounced in patients
treated with IL-2. In contrast to their preoperative levels, the
postoperative kinetics of B-cell marker CD19 and progenitor cell
marker CD34 was not significantly different between both groups.
Monocyte marker CD14 was significantly decreased on day  6 and
day 1 in the IL-2 group.
As expected, IL-2 levels were elevated only after administration
of IL-2. Interleukin-2 administration was followed by a significant
counter-regulation of the soluble IL-2 receptor, IL-1-RA, IL-6, and
IL-10. However, the early postoperative increase of IL-6 and IL-10
was significantly less pronounced in treated patients. No changes
were found for TGF-b1 and VEGF during IL-2 treatment. Both
cytokines showed a postoperative decrease, but were not
significantly different between the study groups.
Follow-up
At the time of analysis, 96 patients were alive, 90 of whom had no
evidence of disease. The median follow-up for surviving patients
was 40 months (range 1–80 months).
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5-year rates (7s.e.m.) of tumour-specific survival were 98%
(72%) and 86% (77%) in the IL-2 group and 81% (75%) and
73% (76%) in the control group, respectively (P¼0.043;
Figure 3A). The median survival time was not reached in either
study group. A similar effect was found for progression-free
survival: 1- and 5-year progression-free survival rates (7s.e.m.)
for patients were 94% (74%) and 81% (78%) in the IL-2 group,
and 74% (76%) and 62% (77%) in the control group,
respectively (P¼0.019; Figure 3B). Median time to tumour
progression was not reached in either group.
Patients with stage IV disease were addressed separately,
because they received the following therapies after nephrectomy:
four patients of each group immunochemotherapy (Hanover
regimen: IL-2, IFN-a, 5-FU), four patients (IL-2 group: three;
control group: one) mistletoe treatment, two patients (one of each
group) surgical resection of lung metastases, one patient (IL-2
group) IFN-a and vinblastine, and one (IL-2 group) local
immunotherapy with inhaled IL-2. The median tumour-specific
survival time was 18 (74) months in the IL-2 group and 10 (71)
months in the control group (P¼0.015). Median time to
progression was 14 (74) months and 6 months (71), respectively
(P¼0.006). Because of the small patient population (IL-2 group:
n¼16; control group: n¼9), further subanalysis including a
separate multivariate analysis was not meaningful.
Notably, we found no difference between the different histolo-
gical subtypes with respect to perioperative immunodysfunction
and survival. A more detailed statistical analysis of subgroups was
hampered by the small strata size.
Multivariate analyses were performed using a Cox proportional
hazard model. The following covariates were examined: age, ECOG
PS, tumour stage, Thoenes grade, histological subtype, treatment
with perioperative immunomodulation (yes vs no), leucocytes,
CD3, CD4, CD6, CD8, CD16, CD25, CD28, CD56, CD57, CD69, IL-
1-RA, IL-2, sIL2-R, IL-6, IL-10, TGF-b1, and VEGF at different time
points. The only variables that reached statistical significance
were ECOG PS, tumour stage, Thoenes grade, and perioperative
immunomodulation. These parameters are shown in Table 3.
DISCUSSION
IL-2 is an established and potent immunomodulating agent that
exerts a striking array of pleiotropic effects on numerous target
cells, the most prominent of which is on T lymphocytes (Gaffen
and Liu, 2004). We showed that preoperative treatment with IL-2
effectively modulates perioperative immunodysfunction but causes
only moderate short-term toxicity. The early postoperative nadir
of cellular parameters of the immune system is less pronounced in
IL-2-treated patients. A more detailed discussion of possible
cellular mechanisms of this effect can be found elsewhere (Bo ¨hm
et al, 2002).
Interleukin (IL)-2 modulates not only intravascular but also
intratumoral immunity. Recently, Donskov et al (2002, 2004)
found a positive correlation between numbers of intratumoral
lymphocyte subsets (CD3, CD8, CD57) and both objective response
and survival during IL-2-based immunotherapy. It remains to be
Table 1 Patient demographic, tumour, and operation characteristics
Variable
IL-2 group
(n¼58)
Control group
(n¼58) P-value
Age (years)
Median 64 63 0.248
Range 34–81 36–84
Sex
Female 20 (34%) 22 (38%) 0.699
Male 38 (66%) 36 (62%)
ECOG PS
0 24 (41%) 29 (50%) 0.530
1 28 (48%) 22 (38%)
2 6 (10%) 7 (12%)
Tumour stage (2002)
I 23 (40%) 24 (41%) 0.234
II 6 (10%) 4 (7%)
III 13 (22%) 21 (36%)
IV 16 (28%) 9 (16%)
Tumour diameter (mm)
Median 65 55 0.451
Range 18–200 17–150
Thoenes grade
G1 9 (16%) 12(21%) 0.407
G2 37 (64%) 39 (67%)
G3 12 (21%) 7 (12%)
Histological subtype
Clear cell 51 (88%) 53 (91%) 0.504
Papillary 6 (10%) 3 (5%)
Chromophobe 1 (2%) 2 (3%)
Tumour location
Right-sided 28 (48%) 25 (43%) 0.313
Left-sided 30 (52%) 33 (57%)
Operation time (min)
Median 160 165 0.864
Range 70–345 60–380
Type of incision
Transperitoneal 45 (78%) 42 (72%) 0.520
Flank 13 (22%) 16 (28%)
Blood transfusion, units packed red blood cells
Median 0 0 0.516
Range 0–6 0–6
IL-2¼interleukin-2; ECOG PS¼Eastern Cooperative Oncology Group performance
status.
Table 2 Interleukin-2-related toxicity according to WHO
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Haematological 58 0000
Gastrointestinal
Bilirubin 58 0000
Transaminases 27 14 12 5 0
O r a l 5 3 4100
Nausea/vomiting 41 9800
Diarrhoea 55 3000
Constipation 53 5000
Renal
Blood creatinin 43 13 2 0 0
Pulmonary 58 0000
Fever with drug 9 15 34 0 0
Allergic 58 0000
Cutaneous 9 31 18 0 0
H a i r 5 8 0000
Infection 57 1000
Cardiac
Hypotension 52 0600
Neurotoxicity 58 0000
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function is critical for disease recurrence after nephrectomy.
Administration of IL-2 was started a week before surgery in
order to allow the patient’s immune system enough time to
respond. It was discontinued 1 day before the operation so that
IL-2-related toxicity did not interfere with the operation. In many
immunotherapeutic regimens, IL-2 is administered over a period
of several weeks. During this long period, IL-2-related toxicity is
likely to accumulate, which contributes to low patient compliance.
In contrast, the much shorter preoperative IL-2 regimen used here
was better tolerated. Frequency and severity of side effects were
within the reported range for the dosage used (Brivio et al, 1992,
1996). The newly introduced dose decrement after the initial four
high doses of IL-2 attenuated a counter-regulation encountered in
an earlier regimen (Bo ¨hm et al, 2002). Consistent administration of
metamizole and metoclopramide increased tolerability. Possible
accumulation of IL-2-related toxicity was avoided by limiting the
duration of high-dose IL-2 administration to 2 days and overall
IL-2 administration to 1 week. The dose decrement also enhanced
the effect of IL-2 pretreatment on the elevation of T-cell, NK cell,
and activation markers, and thus on leucocytes reported earlier
(Bo ¨hm et al, 2002).
With this trial design and the timing of preoperative IL-2
administration, maximum perioperative immunomodulation was
achieved in the early postoperative phase when postoperative
immunodysfunction is most pronounced. The authors therefore
speculate that perioperative as opposed to adjuvant immuno-
therapy is effective because it modulates the immune system
during the most critical perioperative phase when its ability to deal
with metastasising tumour cells is at a nadir.
Before the initiation of the study, some thought was spent on its
design. Perioperative immunomodulation is an investigational
approach and not yet a standard therapeutic option. Therefore, a
phase II rather than a phase III trial was designed. A randomised
phase III trial with a power of 0.80 and an alpha error of 0.05
would require more than 250 patients in each group. At the present
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Figure 1 Perioperative changes of cellular markers. Mean and s.e. are indicated. ( ): IL-2 group; ( ): control group.
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sstage, it appears that it is hardly possible to recruit so many
patients, because ethical concerns may arise besides the organisa-
tional challenge. To our knowledge, no randomised trial of
perioperative immunomodulation has been conducted so far on
any malignancy, and the size of the verum group rarely exceeded
20 patients in published studies (Bo ¨hm et al, 2003). For these
reasons, we opted for a well-controlled non-randomised phase II
trial rather than a randomised trial. Keeping also in mind that
newer therapeutic approaches focus not only on the immune
system but also on other biological pathways such as the VEGF
pathway and tyrosine kinase inhibition, a rather broad array of
markers was assessed.
It appears that after preoperative administration of IL-2,
the perioperative alterations of immunological parameters
are most pronounced in the early post-operative period
(Bo ¨hm et al, 2001). After the 10th post-operative day,
these alterations are rather minor (Deehan et al, 1995)
and can be biased by other factors. For these reasons, immuno-
logical parameters were measured during the first 10 days after
surgery.
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Figure 2 Perioperative changes of cytokines. Presentation of data as in Figure 1.
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Figure 3 Kaplan–Meier survival estimates of patients treated with IL-2 ( , IL-2 group) and without treatment ( , control group) according to (A)
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IL-2-treated patients. However, this study was not randomised and
thus we should not over-interpret the results. We calculated the
power of the trial to be 0.17. To reach a power of 0.80 and an alpha
error of 0.05, we estimated that more than 250 patients would
be required in each group. Therefore, we propose that to validate
our survival data, future studies incorporate the approach of
perioperative immunomodulation whenever possible into pro-
spective, randomised phase III trials.
Two large studies showed that tumour nephrectomy followed by
immunotherapy results in longer survival of patients with
metastatic renal cell cancer (Flanigan et al, 2001; Mickisch et al,
2001). In our study, no adjuvant immunotherapy was adminis-
tered, and only five of 16 patients with metastasised (stage IV) RCC
received systemic immunotherapy according to departmental
guidelines at the time of the trial. This does not warrant subgroup
stratification. It also suggests that the survival data reported here
are not corrupted by subsequent systemic immunotherapy.
Tumour-specific survival in the control group is comparable with
that recently reported by other groups (Motzer et al, 1999;
Flanigan et al, 2001; Mickisch et al, 2001; Atzpodien et al, 2003;
Verra et al, 2003; Atkins et al, 2004), suggesting that a
representative and reliable patient population was assessed here.
None of the stage I patients died of recurrent disease, but two of
24 (8%) control patients and none of the IL-2-treated patients had
a tumour recurrence during follow-up. Because recurrence is
uncommon but does occur among stage I patients (Ljungberg et al,
1999; Gofrit et al, 2001; Pantuck et al, 2001; Zisman et al, 2002), we
included these patients in our trial. Owing to the small number of
events and the short follow-up, it is not feasible to assess these
patients statistically.
In the early postoperative period, TGF-b1 and VEGF decreased,
but no effect of IL-2 treatment was demonstrated. It appears that
IL-2 may not interfere with newer VEGF pathway-targeted tyrosine
kinase inhibitor therapies. Possibly, a combination with these
therapies may be promising.
Taken together, our results indicate that preoperative treatment
with IL-2 may be a feasible, yet investigational approach to
complement surgical therapy and modulate some alterations of the
immune system that occur perioperatively in patients undergoing
tumour nephrectomy. As mentioned above, a larger randomised
trial will be needed to validate the survival data.
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